Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003563 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
A Phase 3 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
NCT00003563 is a Phase 3 study that has completed, run by Pharmacyclics. The registered enrollment target is 430 participants.
The verdict
NCT00003563, a Phase 3 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gadolinium texaphyrin may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation. It is not yet known whether giving gadolinium texaphyrin with radiation therapy is more effective than radiation therapy alone in treating brain metastases. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without gadolinium texaphyrin in treating patients who have brain metastases.
Interventions
- RADIATION WBRT
- DRUG MGd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 1998-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003563
The ClinicalTrials.gov registry entry for NCT00003563 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which WBRT is the first listed.
NCT00003563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003563 about?
NCT00003563 is a clinical study titled "Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gadolinium texaphyrin may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation. It is not yet known whether giving gadolinium texaphyrin with radiation therapy is more effective t...
What is the current status of trial NCT00003563?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 1998-08. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00003563?
The interventions under investigation include: WBRT (RADIATION), MGd (DRUG).
Who is sponsoring clinical trial NCT00003563?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.